Not Cleared Post-NSE

DEN120013 - PORTRAIT ANALYZER (FDA 510(k) Clearance)

Class I Microbiology device.

Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Apr 2012
Decision
59d
Days
Class 1
Risk

DEN120013 is an FDA 510(k) submission (not cleared) for the PORTRAIT ANALYZER. Classified as C. Difficile Nucleic Acid Amplification Test Assay (product code OMN), Class I - General Controls.

Submitted by Great Basin Scientific (Salt Lake City, US). The FDA issued a Not Cleared (DENG) decision on April 30, 2012 after a review of 59 days.

This device falls under the Microbiology FDA review panel, regulated under 21 CFR 866.2660 - the FDA microbiology device framework. The Traditional 510(k) pathway requires demonstration of substantial equivalence to a legally marketed predicate device - a standard the FDA determined was not met in this submission.

Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. This submission did not achieve clearance, indicating the FDA determined the device lacked sufficient predicate equivalence under the Microbiology review framework.

View all Great Basin Scientific devices

Submission Details

510(k) Number DEN120013 FDA.gov
FDA Decision Not Cleared Not Substantially Equivalent (DENG)
Date Received March 02, 2012
Decision Date April 30, 2012
Days to Decision 59 days
Submission Type Post-NSE
Review Panel Microbiology (MI)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
43d faster than avg
Panel avg: 102d · This submission: 59d
Pathway characteristics

Device Classification

Product Code OMN C. Difficile Nucleic Acid Amplification Test Assay
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 866.2660
Definition In Vitro Diagnostic Test For The Qualitative Detection Of Toxigenic Clostridium Difficile Nucleic Acids Isolated And Purified From Stool Specimens Obtained From Symptomatic Patients.
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.